Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

Jean Pascal Lefaucheur, Nathalie André-Obadia, Andrea Antal, Samar S. Ayache, Chris Baeken, David H. Benninger, Roberto M. Cantello, Massimo Cincotta, Mamede de Carvalho, Dirk De Ridder, Hervé Devanne, Vincenzo Di Lazzaro, Saša R. Filipović, Friedhelm C. Hummel, Satu K. Jääskeläinen, Vasilios K. Kimiskidis, Giacomo Koch, Berthold Langguth, Thomas Nyffeler, Antonio OlivieroFrank Padberg, Emmanuel Poulet, Simone Rossi, Paolo Maria Rossini, John C. Rothwell, Carlos Schönfeldt-Lecuona, Hartwig R. Siebner, Christina W. Slotema, Charlotte J. Stagg, Josep Valls-Sole, Ulf Ziemann, Walter Paulus, Luis Garcia-Larrea

Research output: Contribution to journalArticle

782 Citations (Scopus)

Abstract

A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

Original languageEnglish
Pages (from-to)2150-2206
Number of pages57
JournalClinical Neurophysiology
Volume125
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Transcranial Magnetic Stimulation
Therapeutic Uses
Guidelines
Prefrontal Cortex
Tinnitus
Antidepressive Agents
Schizophrenia
Stroke
Consciousness Disorders
Somatoform Disorders
Hallucinations
Obsessive-Compulsive Disorder
Movement Disorders
Amyotrophic Lateral Sclerosis
Motor Cortex
Anxiety Disorders
Multiple Sclerosis
Analgesics
Epilepsy
Patient Care

Keywords

  • Cortex
  • Indication
  • Neurological disease
  • Neuromodulation
  • Noninvasive brain stimulation
  • Psychiatric disease
  • TMS
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)
  • Sensory Systems

Cite this

Lefaucheur, J. P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., ... Garcia-Larrea, L. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 125(11), 2150-2206. https://doi.org/10.1016/j.clinph.2014.05.021

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). / Lefaucheur, Jean Pascal; André-Obadia, Nathalie; Antal, Andrea; Ayache, Samar S.; Baeken, Chris; Benninger, David H.; Cantello, Roberto M.; Cincotta, Massimo; de Carvalho, Mamede; De Ridder, Dirk; Devanne, Hervé; Di Lazzaro, Vincenzo; Filipović, Saša R.; Hummel, Friedhelm C.; Jääskeläinen, Satu K.; Kimiskidis, Vasilios K.; Koch, Giacomo; Langguth, Berthold; Nyffeler, Thomas; Oliviero, Antonio; Padberg, Frank; Poulet, Emmanuel; Rossi, Simone; Rossini, Paolo Maria; Rothwell, John C.; Schönfeldt-Lecuona, Carlos; Siebner, Hartwig R.; Slotema, Christina W.; Stagg, Charlotte J.; Valls-Sole, Josep; Ziemann, Ulf; Paulus, Walter; Garcia-Larrea, Luis.

In: Clinical Neurophysiology, Vol. 125, No. 11, 2014, p. 2150-2206.

Research output: Contribution to journalArticle

Lefaucheur, JP, André-Obadia, N, Antal, A, Ayache, SS, Baeken, C, Benninger, DH, Cantello, RM, Cincotta, M, de Carvalho, M, De Ridder, D, Devanne, H, Di Lazzaro, V, Filipović, SR, Hummel, FC, Jääskeläinen, SK, Kimiskidis, VK, Koch, G, Langguth, B, Nyffeler, T, Oliviero, A, Padberg, F, Poulet, E, Rossi, S, Rossini, PM, Rothwell, JC, Schönfeldt-Lecuona, C, Siebner, HR, Slotema, CW, Stagg, CJ, Valls-Sole, J, Ziemann, U, Paulus, W & Garcia-Larrea, L 2014, 'Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)', Clinical Neurophysiology, vol. 125, no. 11, pp. 2150-2206. https://doi.org/10.1016/j.clinph.2014.05.021
Lefaucheur, Jean Pascal ; André-Obadia, Nathalie ; Antal, Andrea ; Ayache, Samar S. ; Baeken, Chris ; Benninger, David H. ; Cantello, Roberto M. ; Cincotta, Massimo ; de Carvalho, Mamede ; De Ridder, Dirk ; Devanne, Hervé ; Di Lazzaro, Vincenzo ; Filipović, Saša R. ; Hummel, Friedhelm C. ; Jääskeläinen, Satu K. ; Kimiskidis, Vasilios K. ; Koch, Giacomo ; Langguth, Berthold ; Nyffeler, Thomas ; Oliviero, Antonio ; Padberg, Frank ; Poulet, Emmanuel ; Rossi, Simone ; Rossini, Paolo Maria ; Rothwell, John C. ; Schönfeldt-Lecuona, Carlos ; Siebner, Hartwig R. ; Slotema, Christina W. ; Stagg, Charlotte J. ; Valls-Sole, Josep ; Ziemann, Ulf ; Paulus, Walter ; Garcia-Larrea, Luis. / Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). In: Clinical Neurophysiology. 2014 ; Vol. 125, No. 11. pp. 2150-2206.
@article{def08865839f41cdbf2493ea38802451,
title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)",
abstract = "A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.",
keywords = "Cortex, Indication, Neurological disease, Neuromodulation, Noninvasive brain stimulation, Psychiatric disease, TMS, Treatment",
author = "Lefaucheur, {Jean Pascal} and Nathalie Andr{\'e}-Obadia and Andrea Antal and Ayache, {Samar S.} and Chris Baeken and Benninger, {David H.} and Cantello, {Roberto M.} and Massimo Cincotta and {de Carvalho}, Mamede and {De Ridder}, Dirk and Herv{\'e} Devanne and {Di Lazzaro}, Vincenzo and Filipović, {Saša R.} and Hummel, {Friedhelm C.} and J{\"a}{\"a}skel{\"a}inen, {Satu K.} and Kimiskidis, {Vasilios K.} and Giacomo Koch and Berthold Langguth and Thomas Nyffeler and Antonio Oliviero and Frank Padberg and Emmanuel Poulet and Simone Rossi and Rossini, {Paolo Maria} and Rothwell, {John C.} and Carlos Sch{\"o}nfeldt-Lecuona and Siebner, {Hartwig R.} and Slotema, {Christina W.} and Stagg, {Charlotte J.} and Josep Valls-Sole and Ulf Ziemann and Walter Paulus and Luis Garcia-Larrea",
year = "2014",
doi = "10.1016/j.clinph.2014.05.021",
language = "English",
volume = "125",
pages = "2150--2206",
journal = "Clinical Neurophysiology",
issn = "1388-2457",
publisher = "Elsevier Ireland Ltd",
number = "11",

}

TY - JOUR

T1 - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

AU - Lefaucheur, Jean Pascal

AU - André-Obadia, Nathalie

AU - Antal, Andrea

AU - Ayache, Samar S.

AU - Baeken, Chris

AU - Benninger, David H.

AU - Cantello, Roberto M.

AU - Cincotta, Massimo

AU - de Carvalho, Mamede

AU - De Ridder, Dirk

AU - Devanne, Hervé

AU - Di Lazzaro, Vincenzo

AU - Filipović, Saša R.

AU - Hummel, Friedhelm C.

AU - Jääskeläinen, Satu K.

AU - Kimiskidis, Vasilios K.

AU - Koch, Giacomo

AU - Langguth, Berthold

AU - Nyffeler, Thomas

AU - Oliviero, Antonio

AU - Padberg, Frank

AU - Poulet, Emmanuel

AU - Rossi, Simone

AU - Rossini, Paolo Maria

AU - Rothwell, John C.

AU - Schönfeldt-Lecuona, Carlos

AU - Siebner, Hartwig R.

AU - Slotema, Christina W.

AU - Stagg, Charlotte J.

AU - Valls-Sole, Josep

AU - Ziemann, Ulf

AU - Paulus, Walter

AU - Garcia-Larrea, Luis

PY - 2014

Y1 - 2014

N2 - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

AB - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

KW - Cortex

KW - Indication

KW - Neurological disease

KW - Neuromodulation

KW - Noninvasive brain stimulation

KW - Psychiatric disease

KW - TMS

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84927691583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927691583&partnerID=8YFLogxK

U2 - 10.1016/j.clinph.2014.05.021

DO - 10.1016/j.clinph.2014.05.021

M3 - Article

C2 - 25034472

AN - SCOPUS:84927691583

VL - 125

SP - 2150

EP - 2206

JO - Clinical Neurophysiology

JF - Clinical Neurophysiology

SN - 1388-2457

IS - 11

ER -